12.25
-0.61 (-4.74%)
| Previous Close | 12.86 |
| Open | 12.81 |
| Volume | 1,711,475 |
| Avg. Volume (3M) | 1,282,919 |
| Market Cap | 1,027,055,872 |
| Price / Sales | 126.01 |
| Price / Book | 4.51 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2026 |
| Profit Margin | -261.91% |
| Operating Margin (TTM) | -199.72% |
| Diluted EPS (TTM) | -2.42 |
| Quarterly Revenue Growth (YOY) | 109.30% |
| Total Debt/Equity (MRQ) | 8.07% |
| Current Ratio (MRQ) | 7.85 |
| Operating Cash Flow (TTM) | -148.18 M |
| Levered Free Cash Flow (TTM) | -82.41 M |
| Return on Assets (TTM) | -29.16% |
| Return on Equity (TTM) | -53.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | EyePoint, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.83 |
|
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 3.46% |
| % Held by Institutions | 109.22% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |